Australia's lifesaving drug scheme review could require new evidence of real-life benefits
This article was originally published in Scrip
Executive Summary
Companies with drugs subsidized through the Australian Life Saving Drugs Programme (LSDP) may in future have to provide updated evidence of their products' real-life benefits or accept a price cut or delisting from the scheme, if proposals put forward in a government consultation document are taken forward.
You may also be interested in...
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.
UK Industry Gets More Time To Adapt To Post-Brexit Import Rules
The BioIndustry Association has welcomed a decision to delay the deadline for compliance with new regulations on the classification of imported materials used in drug production, but says the border rules are still not proportionate for life science products.